[Preliminary results of treatment with Tagamet (cimetidine SK and F) in gastric and duodenal ulcers]. 1978

M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello

Following 3x200 mg Tagament (cymetidine SK & F) tablets at meals and 2 in the evening (5 per day) for an average of 31 days, complete endoscopic cure was obtained after 29 days (duodenal patients) and 35 days (gastric patients) in 26/27 subjects with slow healing histories (17 with duodenal and 10 with gastric ulcer). Rapid regression of pain and dyspepsia was observed form the outset and there was a marked reduction in the consumption of antacid preparation. Its marked efficacy and good tolerance make Tagamet a drug of choice in the treatment of peptic, duodenal and gastric ulcers.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010437 Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastroduodenal Ulcer,Marginal Ulcer,Gastroduodenal Ulcers,Marginal Ulcers,Peptic Ulcers,Ulcer, Gastroduodenal,Ulcer, Marginal,Ulcer, Peptic,Ulcers, Gastroduodenal,Ulcers, Marginal,Ulcers, Peptic
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
January 1979, Vutreshni bolesti,
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
October 1977, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
November 1979, Ugeskrift for laeger,
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
March 1970, Revista espanola de las enfermedades del aparato digestivo,
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
November 1953, Helvetica chirurgica acta,
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
November 1969, Hospital (Rio de Janeiro, Brazil),
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
January 1986, Digestive diseases and sciences,
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
February 1981, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
January 1985, Lancet (London, England),
M Cambielli, and A Evangelista, and P A Testoni, and C Benvenuti, and A Tittobello
October 1986, Gut,
Copied contents to your clipboard!